- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:14 | Invitation to FluoGuide A/S Live Webcast on 25 August 2026 | 160 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / August 12, 2026 / FluoGuide A/S (STO:FLUO) will publish its interim report for Q2 2026 on Tuesday, 25 August 2026.Later that day, CEO Morten Albrechtsen and CFO Ole... ► Artikel lesen | |
| 01.07. | FluoGuide A/S: Update on 2026 Outlook and Company Progress | 357 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / July 1, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a clinical-stage biotech company focused on precision cancer surgery, is pleased to share an... ► Artikel lesen | |
| 29.06. | FluoGuide A/S: FluoGuide Announces Positive Results from Phase 2 Oral, Head and Neck Cancer Trial | 356 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / June 29, 2026 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced... ► Artikel lesen | |
| 27.05. | FluoGuide A/S Publishes Interim Report for Q1 2026 | 394 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / May 27, 2026 / Fluoguide A/S (STO:FLUO) ("FluoGuide" or the "Company") today releases its results for the period 1 January 2026 - 31 March 2026. The Q1 report is available... ► Artikel lesen | |
| 13.05. | Invitation to FluoGuide A/S Live Webcast on 27 May 2026 | 321 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / May 13, 2026 / FluoGuide A/S (STO:FLUO) will publish its interim report for Q1 2026 on Wednesday, 27 May 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen... ► Artikel lesen | |
| FLUOGUIDE Aktie jetzt für 0€ handeln | |||||
| 10.04. | FluoGuide A/S: Positive interim results from an investigator-initiated study of FG001 in meningioma and low-grade glioma surgery, re-presented at SNOG | 195 | GlobeNewswire (Europe) | Copenhagen, Denmark, 10 April 2026 - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company maximizing surgical outcomes in oncology by lighting up cancer.
The interim data from... ► Artikel lesen | |
| 25.03. | Minutes from Annual General Meeting in FluoGuide A/S | 447 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 25, 2026 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company") held its annual general meeting on 25 March 2026.To the shareholders of FluoGuide A/S.The... ► Artikel lesen | |
| 18.03. | FluoGuide A/S: FluoGuide Receives FDA Fast Track Designation for FG001 in High-Grade Glioma | 368 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 18, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, announces... ► Artikel lesen | |
| 10.03. | Notice of Annual General Meeting in FluoGuide A/S | 479 | ACCESS Newswire | KØBENHAVN, DENMARK / ACCESS Newswire / March 10, 2026 / FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39... ► Artikel lesen | |
| 25.02. | FluoGuide A/S Publishes Annual Report For The Fiscal Year 2025 | 553 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO) hereby publishes its annual report for the fiscal year 2025. The annual report, including... ► Artikel lesen | |
| 25.02. | FluoGuide A/S Publishes Interim Report For Q4 2025 | 370 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / Fluoguide A/S ("FluoGuide" or the "Company")(STO:FLUO) today releases its results for the period 1 January 2025 - 31 December 2025. The Q4 report... ► Artikel lesen | |
| 20.02. | FluoGuide A/S: FDA Clears FluoGuide's IND for FG001 in High-Grade Glioma; U.S. Clinical Trial Remains on Track | 721 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / February 20, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer... ► Artikel lesen | |
| 19.02. | Invitation to FluoGuide A/S Live Webcast on 25 February 2026 | 295 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / February 19, 2026 / FluoGuide A/S (STO:FLUO) will publish its Annual Report 2025 on Wednesday, 25 February 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen... ► Artikel lesen | |
| 21.01. | FluoGuide A/S: FluoGuide Submits an IND for FG001, to Initiate First U.S. Registration Trial | 343 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / January 21, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced... ► Artikel lesen | |
| 27.11.25 | FluoGuide A/S Publishes Interim Report Q3 2025 | 453 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 27, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO) today releases its results for the period 1 January - 30 September 2025. The Q3 report is... ► Artikel lesen | |
| 25.11.25 | FluoGuide A/S: FluoGuide Signs Collaboration Agreement with ZEISS | 481 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 25, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 25 November 2025 - FluoGuide A/S, a biotech company specializing in precision cancer surgery, announces... ► Artikel lesen | |
| 24.11.25 | Minutes from Extraordinary General Meeting in FluoGuide A/S | 390 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company" held an extraordinary general meeting on 24 November 2025.To the shareholders of FluoGuide... ► Artikel lesen | |
| 24.11.25 | Invitation to FluoGuide A/S Webcast on 27 November 2025 | 379 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q3 2025 on Thursday 27 November 2025.The following event will take place... ► Artikel lesen | |
| 05.11.25 | FluoGuide A/S: FluoGuide Strengthens Leadership to Advance Clinical Program and Regulatory Approval Strategy | 463 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 5, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces changes to both its... ► Artikel lesen | |
| 05.11.25 | FluoGuide A/S: FluoGuide Convenes an Extraordinary General Meeting | 392 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / November 5, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") hereby invites shareholders to participate in an extraordinary general meeting to be... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRIGHTSPRING HEALTH SERVICES | 57,92 | +0,05 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,780 | -0,07 % | GOLDMAN SACHS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für FMC von 43 auf 39 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Analyst Richard Felton passte seine... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 11,510 | +0,09 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 13,180 | 0,00 % | Can ALHC's Raised 2026 Outlook Offset Heavier Second-Half Spending? | ||
| BILLIONTOONE | 97,74 | -0,20 % | Diagnostiksektor: BTIG kürt BillionToOne zum Top-Pick | ||
| PROGYNY | 26,560 | -0,04 % | Progyny, Inc. Announces Second Quarter 2026 Results | Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDARobust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building SolutionsValue Returned to Shareholders... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 39,540 | -0,13 % | Siemens macht Fortschritte bei Abspaltung von Healthineers | MÜNCHEN (dpa-AFX) - Der Technologiekonzern Siemens kommt bei der geplanten Abspaltung seiner Medizintechniktochter Siemens Healthineers voran. So seien die relevanten steuerlichen Themen mit den Finanzbehörden... ► Artikel lesen | |
| GENEDX | 81,84 | 0,00 % | GeneDx launches online exome testing for pediatric patients | ||
| FRESENIUS | 46,980 | -0,36 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 22,910 | +0,09 % | Jefferies senkt Kursziel für Procept BioRobotics nach verfehlten Eingriffszahlen | ||
| AVEANNA HEALTHCARE | 8,935 | -0,17 % | Will Lower PDS Margin Affect Aveanna Healthcare's Q2 Earnings? | ||
| ADAPTHEALTH | 5,640 | -0,18 % | Truist cuts AdaptHealth stock price target on Q2 challenges | ||
| PRIVIA HEALTH GROUP | 21,990 | +0,05 % | Privia Health Group, Inc.: Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results | 2Q'26 Net Income of $9.0M, +236.7% from 2Q'252Q'26 Adjusted EBITDA of $37.4M, +29.1% from 2Q'25Full-Year 2026 Guidance Raised for All Key Financial Metrics ARLINGTON, Va., Aug. 06, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| SANARA MEDTECH | 34,360 | 0,00 % | Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited) | FORT WORTH, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," "Sanara MedTech," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing... ► Artikel lesen | |
| STARLING ONCOLOGY INSTITUTE | 6,200 | +0,08 % | Earnings Call: Starling Oncology übertrifft Umsatzprognose für Q2 2026, Aktie legt nachbörslich zu |
FLUOGUIDE A/S gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,010 (-0,38 %) liegt der Kurs bei 2,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLUOGUIDE A/S finden Sie auf Wallstreet Online.